{
    "clinical_study": {
        "@rank": "48403", 
        "arm_group": {
            "arm_group_label": "Xeloda", 
            "arm_group_type": "Experimental", 
            "description": "Xeloda"
        }, 
        "brief_summary": {
            "textblock": "Select 600 cases of women with breast cancer of triple negative or Her-2 positive or with\n      more than 4 axillary lymph node metastasis. All the patients were accepted the chemotherapy\n      of Anthracycline and/or Taxane. Divide them into two groups randomly. Then the experimental\n      group will be treated with Xeloda(1000mg/m2,orally,2 times/day) for six cycles (21\n      days/cycle,each taking two weeks suspending for one week) as Sequential Adjuvant Therapy.\n      And the control group will not receive any adjuvant therapy.Finally the investigators will\n      assess the 5-year disease-free survival, 5 years and 10-year overall survival and safety of\n      using medications."
        }, 
        "brief_title": "Efficacy and Safety Of Xeloda as Sequential Adjuvant Therapy After Chemotherapy in Breast Cancer", 
        "completion_date": {
            "#text": "June 2022", 
            "@type": "Anticipated"
        }, 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "detailed_description": {
            "textblock": "The investigators will select 600 cases of women with breast cancer of triple negative or\n      Her-2 positive or with more than 4 axillary lymph node metastasis. All the patients were\n      accepted the chemotherapy of Anthracycline and/or Taxane. Divide them into two groups\n      randomly. Then the experimental group will be treated with Xeloda(1000mg/m2,orally,2\n      times/day) for six cycles (21 days/cycle,each taking two weeks suspending for one week) as\n      Sequential Adjuvant Therapy. And the control group will not receive any adjuvant\n      therapy.Finally the investigators will assess the 5-year disease-free survival, 5 years and\n      10-year overall survival and safety of using medications."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          1. Karnofsky \u2265 70\n\n          2. Provision of informed consent\n\n          3. Pathological confirmation of breast cancer and exclusion of other metastases.\n\n          4. Pathological confirmation of triple negative or Her-2 positive or with more than 4\n             axillary lymph node metastasis\n\n          5. The patients have finished the chemotherapy of Anthracycline and/or Taxane.And it's\n             no more than 28 days from accepting the last chemotherapy.\n\n          6. Laboratory criteria:\n\n        PLT \u2265 100*109/L WBC \u2265 4000/mm3 HGB \u2265 10g/dl GOT,GPT,ALP \u2264 2*ULN TBIL,DBIL,CCr \u2264 1.5*ULN\n\n        Exclusion Criteria:\n\n          1. Pregnant or lactation woman\n\n          2. Bilateral breast cancer, inflammatory breast cancer or carcinoma in situ\n\n          3. Accepted neoadjuvant treatment including chemotherapy, radiotherapy and endocrine\n             therapy\n\n          4. History of organ transplantation\n\n          5. With mental disease\n\n          6. With severe infection or active gastrointestinal ulcers\n\n          7. With severe liver disease (such as cirrhosis), kidney disease, respiratory disease or\n             diabetes\n\n          8. Disease-free period of other malignant tumor is less than 5 years(except cured basal\n             cell skin cancer and cervical carcinoma in situ)\n\n          9. With heart disease\n\n         10. Experimental drug allergy"
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "N/A"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "August 2, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01662128", 
            "org_study_id": "xeloda"
        }, 
        "intervention": {
            "arm_group_label": "Xeloda", 
            "description": "Xeloda as Adjuvant Therapy", 
            "intervention_name": "Xeloda", 
            "intervention_type": "Drug", 
            "other_name": "Xeloda"
        }, 
        "intervention_browse": {
            "mesh_term": "Capecitabine"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "keyword": "Breast Cancer", 
        "lastchanged_date": "August 7, 2012", 
        "location": {
            "contact": {
                "last_name": "ZHANG SHENG, DOCTOR", 
                "phone": "86-022-23340123", 
                "phone_ext": "2901"
            }, 
            "contact_backup": {
                "last_name": "ZHANG SHENG, DORTOR", 
                "phone": "86-022-23340123", 
                "phone_ext": "2901"
            }, 
            "facility": {
                "address": {
                    "city": "Tianjin", 
                    "country": "China", 
                    "state": "Tianjin", 
                    "zip": "300060"
                }, 
                "name": "Tianjin Cancer Hospital"
            }, 
            "investigator": {
                "last_name": "ZHANG JIN, PROFESSOR", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "1", 
        "official_title": "Randomized Controlled Trials of Efficacy and Safety With Xeloda as Sequential Adjuvant Therapy After Chemotherapy of Anthracycline and/or Taxane in Breast Cancer of Triple Negative or HER-2 Positive or Axillary Lymph Node Metastasis \u22654", 
        "other_outcome": {
            "description": "Overall survival,recurrence or death of 10 years", 
            "measure": "Overall survival,recurrence or death", 
            "safety_issue": "Yes", 
            "time_frame": "10 years"
        }, 
        "overall_official": {
            "affiliation": "Tianjin cancer hospital", 
            "last_name": "Jin Zhang, Professor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2/Phase 3", 
        "primary_completion_date": {
            "#text": "June 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "The occurrence of adverse reactions and the number of cases", 
            "measure": "Adverse reactions", 
            "safety_issue": "Yes", 
            "time_frame": "6 months"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01662128"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Tianjin Medical University", 
            "investigator_full_name": "Zhang jin", 
            "investigator_title": "Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": {
            "description": "Disease-free survival of 5 years", 
            "measure": "Disease-free survival", 
            "safety_issue": "Yes", 
            "time_frame": "5 years"
        }, 
        "source": "Tianjin Medical University", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Tianjin Medical University", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "June 2012", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "August 2012"
    }
}